CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 128.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 51.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 44.75.
Overvalued
The company’s latest PE is -3.48, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.50M shares, decreasing 11.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.08M shares of this stock.